Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Locally Advanced Pancreatic Carcinoma(LAPC) Clear all
Suspended Phase 2 Interventional

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

NCT05494697
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Rintatolimod
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Omaha, Nebraska • Canton, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 10, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

NCT02301143
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Gemcitabine, Chemoradiation, Capecitabine, Surgery
Drug · Procedure
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jun 10, 2026, 7:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

NCT00831493
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Chemoradiation (Radiation Therapy), Vorinostat
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jun 10, 2026, 7:24 PM EDT
Active, not recruiting No phase listed Observational

A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

NCT03899649
View directory record Official record
Conditions
Stage III Pancreatic Cancer
Interventions
SOC, NanoKnife System
Drug · Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
La Jolla, California • Gainesville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jun 10, 2026, 7:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

NCT03899636
View directory record Official record
Conditions
Stage III Pancreatic Cancer
Interventions
Modified FOLFIRINOX Regimen, NanoKnife System
Drug · Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tampa, Florida • Arlington Heights, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jun 10, 2026, 7:24 PM EDT
Recruiting Phase 3 Interventional

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
279
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 210 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 10, 2026, 7:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

NCT03767582
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Interventions
Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist, GVAX
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 10, 2026, 7:24 PM EDT
Not yet recruiting Phase 1 Interventional

Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

NCT06217666
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
PCX-12
Drug
Lead sponsor
Haoming (Carl) Qiu
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 10, 2026, 7:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

NCT03652428
View directory record Official record
Conditions
Locally Advanced Pancreatic Cancer
Interventions
Gemcitabine, Hypofractionated Ablative Proton Therapy
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

NCT02873598
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
FOLFIRINOX or gemcitabine/abraxane, SBRT
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Jun 10, 2026, 7:24 PM EDT
Terminated Not applicable Interventional Results available

Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer

NCT01683422
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton, Gemcitabine, Erlotinib, Capecitabine, Proton Radiation
Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Jun 10, 2026, 7:24 PM EDT
Recruiting Phase 3 Interventional

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

NCT03257033
View directory record Official record
Conditions
Locally Advanced Pancreatic Cancer
Interventions
Gemcitabine, nab-paclitaxel, RenovoCath
Drug · Device
Lead sponsor
RenovoRx
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
36
States / cities
Loma Linda, California • Sacramento, California • Denver, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 10, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

NCT03861702
View directory record Official record
Conditions
Locally Advanced Pancreatic Carcinoma(LAPC)
Interventions
FOLFOX regimen, Liposomal Irinotecan
Drug
Lead sponsor
Nelson Yee
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jun 10, 2026, 7:24 PM EDT